## Table 1: Association between Exposure to IPV and Child Immune Status

| Maternal Exposure to IPV | Outcome | N | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Adjusted | | | |
|  |  |  | Predicted Outcome no Exposure | Predicted Outcome with Exposure | Coefficient (95% CI) | P-value |
| Exposure to IPV during pregnancy | Sum score of inflammation Year 1 | 261 | 0.01 | 0.01 | 0.01 (-0.29, 0.3) | 0.97 |
|  | Ln Th1/Th2 Year 1 | 259 | -0.08 | -0.01 | 0.07 (-0.07, 0.21) | 0.34 |
|  | Ln Th1/Th17 Year 1 | 253 | 0.2 | 0.37 | 0.17 (0.02, 0.32) | 0.03 |
|  | Ln Th1/IL-10 Year 1 | 260 | 1.05 | 1.12 | 0.07 (-0.06, 0.21) | 0.31 |
|  | Ln Th2/IL-10 Year 1 | 260 | 1.18 | 1.2 | 0.02 (-0.16, 0.2) | 0.8 |
|  | Ln Th17/IL-10 Year 1 | 254 | 0.71 | 0.63 | -0.09 (-0.28, 0.11) | 0.4 |
|  | Ln GM-CSF/IL-10 Year 1 | 261 | 1.79 | 1.71 | -0.08 (-0.33, 0.17) | 0.53 |
|  | Ln IL-2/IL-10 Year 1 | 256 | -2.8 | -2.97 | -0.16 (-0.53, 0.21) | 0.4 |
|  | Ln IFN-y Year 1 | 261 | 1.89 | 1.97 | 0.09 (-0.07, 0.24) | 0.29 |
|  | Ln CRP Year 1 | 240 | 0.23 | 0.36 | 0.13 (-0.44, 0.71) | 0.66 |
|  | Ln AGP Year 1 | 233 | 0.14 | 0.25 | 0.11 (-0.03, 0.24) | 0.12 |
|  | Ln IGF-1 Year 1 | 234 | 3.26 | 3.3 | 0.04 (-0.17, 0.24) | 0.75 |
|  |  |  |  |  |  |  |
|  | Sum score of inflammation Year 2 | 348 | 0.04 | -0.12 | -0.16 (-0.4, 0.08) | 0.2 |
|  | Ln Th1/Th2 Year 2 | 305 | -0.03 | 0.1 | 0.13 (-0.01, 0.28) | 0.07 |
|  | Ln Th1/Th17 Year 2 | 302 | 0.52 | 0.57 | 0.05 (-0.08, 0.17) | 0.46 |
|  | Ln Th1/IL-10 Year 2 | 344 | 1.35 | 1.43 | 0.09 (-0.06, 0.23) | 0.26 |
|  | Ln Th2/IL-10 Year 2 | 344 | 1.3 | 1.31 | 0.01 (-0.15, 0.17) | 0.89 |
|  | Ln Th17/IL-10 Year 2 | 340 | 0.97 | 1.07 | 0.1 (-0.06, 0.26) | 0.23 |
|  | Ln GM-CSF/IL-10 Year 2 | 348 | 2.33 | 2.44 | 0.1 (-0.15, 0.36) | 0.44 |
|  | Ln IL-2/IL-10 Year 2 | 297 | -2.36 | -2.42 | -0.06 (-0.41, 0.29) | 0.75 |
|  | Ln IFN-y Year 2 | 307 | 1.97 | 1.91 | -0.06 (-0.23, 0.11) | 0.47 |
|  | Ln CRP Year 2 | 655 | -0.31 | -0.41 | -0.11 (-0.37, 0.16) | 0.44 |
|  | Ln AGP Year 2 | 394 | -0.24 | -0.25 | -0.01 (-0.01, -0.01) | 0\* |
|  | Ln IGF-1 Year 2 | 363 | 3.9 | 3.94 | 0.04 (-0.08, 0.16) | 0.53 |
|  |  |  |  |  |  |  |
| Exposure to IPV during first year of child's life | Sum score of inflammation Year 1 | 270 | -0.03 | 0.05 | 0.07 (-0.18, 0.33) | 0.59 |
|  | Ln Th1/Th2 Year 1 | 267 | -0.07 | -0.06 | 0.01 (-0.11, 0.14) | 0.83 |
|  | Ln Th1/Th17 Year 1 | 261 | 0.23 | 0.27 | 0.05 (-0.09, 0.19) | 0.53 |
|  | Ln Th1/IL-10 Year 1 | 269 | 1.06 | 1.11 | 0.04 (-0.07, 0.15) | 0.47 |
|  | Ln Th2/IL-10 Year 1 | 268 | 1.28 | 1.31 | 0.03 (-0.12, 0.18) | 0.7 |
|  | Ln Th17/IL-10 Year 1 | 262 | 0.79 | 0.78 | -0.01 (-0.16, 0.15) | 0.93 |
|  | Ln GM-CSF/IL-10 Year 1 | 270 | 2.08 | 2.06 | -0.02 (-0.24, 0.2) | 0.87 |
|  | Ln IL-2/IL-10 Year 1 | 265 | -2.73 | -2.74 | -0.01 (-0.33, 0.3) | 0.94 |
|  | Ln IFN-y Year 1 | 270 | 1.85 | 1.92 | 0.07 (-0.07, 0.2) | 0.35 |
|  | Ln CRP Year 1 | 250 | 0.22 | 0.32 | 0.1 (-0.36, 0.55) | 0.69 |
|  | Ln AGP Year 1 | 241 | 0.04 | 0.06 | 0.02 (-0.09, 0.14) | 0.72 |
|  | Ln IGF-1 Year 1 | 242 | 3.28 | 3.29 | 0 (-0.18, 0.18) | 0.99 |
|  |  |  |  |  |  |  |
|  | Sum score of inflammation Year 2 | 363 | -0.03 | -0.07 | -0.04 (-0.24, 0.16) | 0.7 |
|  | Ln Th1/Th2 Year 2 | 320 | -0.04 | -0.16 | -0.12 (-0.24, 0.01) | 0.06 |
|  | Ln Th1/Th17 Year 2 | 316 | 0.47 | 0.5 | 0.03 (-0.07, 0.14) | 0.55 |
|  | Ln Th1/IL-10 Year 2 | 358 | 1.36 | 1.28 | -0.07 (-0.2, 0.05) | 0.25 |
|  | Ln Th2/IL-10 Year 2 | 359 | 1.24 | 1.27 | 0.03 (-0.1, 0.16) | 0.68 |
|  | Ln Th17/IL-10 Year 2 | 354 | 0.94 | 0.86 | -0.08 (-0.21, 0.05) | 0.24 |
|  | Ln GM-CSF/IL-10 Year 2 | 365 | 2.33 | 2.36 | 0.04 (-0.18, 0.25) | 0.76 |
|  | Ln IL-2/IL-10 Year 2 | 312 | -2.41 | -2.18 | 0.22 (-0.06, 0.51) | 0.12 |
|  | Ln IFN-y Year 2 | 322 | 1.93 | 1.82 | -0.11 (-0.25, 0.04) | 0.14 |
|  | Ln CRP Year 2 | 683 | -0.3 | -0.42 | -0.12 (-0.34, 0.11) | 0.31 |
|  | Ln AGP Year 2 | 413 | -0.2 | -0.19 | 0.01 (-0.09, 0.12) | 0.81 |
|  | Ln IGF-1 Year 2 | 379 | 3.91 | 3.91 | 0 (-0.09, 0.1) | 0.95 |
|  |  |  |  |  |  |  |
| Cumulative lifetime exposure to IPV | Sum score of inflammation Year 2 | 643 | 0.03 | 0.06 | 0.04 (-0.04, 0.12) | 0.38 |
|  | Ln Th1/Th2 Year 2 | 564 | -0.05 | -0.04 | 0.01 (-0.07, 0.1) | 0.78 |
|  | Ln Th1/Th17 Year 2 | 558 | 0.27 | 0.32 | 0.06 (-0.02, 0.13) | 0.16 |
|  | Ln Th1/IL-10 Year 2 | 637 | 1.39 | 1.37 | -0.02 (-0.06, 0.03) | 0.44 |
|  | Ln Th2/IL-10 Year 2 | 637 | 1.36 | 1.33 | -0.03 (-0.14, 0.07) | 0.56 |
|  | Ln Th17/IL-10 Year 2 | 630 | 0.94 | 0.91 | -0.03 (-0.09, 0.02) | 0.22 |
|  | Ln GM-CSF/IL-10 Year 2 | 650 | 2.28 | 2.39 | 0.11 (-0.04, 0.26) | 0.14 |
|  | Ln IL-2/IL-10 Year 2 | 556 | -2.38 | -2.42 | -0.04 (-0.24, 0.16) | 0.69 |
|  | Ln IFN-y Year 2 | 567 | 1.93 | 1.99 | 0.05 (-0.05, 0.16) | 0.33 |
|  | Ln CRP Year 2 | 1172 | -0.33 | -0.34 | -0.01 (-0.17, 0.15) | 0.9 |
|  | Ln AGP Year 2 | 691 | -0.18 | -0.18 | 0 (-0.07, 0.08) | 0.99 |
|  | Ln IGF-1 Year 2 | 671 | 3.93 | 3.9 | -0.03 (-0.07, 0) | 0.05 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses  \* P-value < 0.2 after adjusting for multiple comparisons using the Benjamini-Hochberg procedure | | | | | | |

## Table 2: Association between Parental Stress and Child Immune Status

| Parental Stress | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Adjusted | | | |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| Maternal stress score | Sum score of inflammation Year 2 | 643 | 10 | 18 | 0.04 | 0.09 | 0.05 (-0.06, 0.17) | 0.36 |
|  | Ln Th1/Th2 Year 2 | 566 | 10 | 18 | -0.03 | -0.07 | -0.03 (-0.09, 0.03) | 0.31 |
|  | Ln Th1/Th17 Year 2 | 560 | 10 | 18 | 0.32 | 0.34 | 0.03 (-0.08, 0.14) | 0.63 |
|  | Ln Th1/IL-10 Year 2 | 637 | 10 | 18 | 1.37 | 1.35 | -0.01 (-0.08, 0.05) | 0.69 |
|  | Ln Th2/IL-10 Year 2 | 639 | 10 | 18 | 1.35 | 1.35 | 0.01 (-0.07, 0.08) | 0.89 |
|  | Ln Th17/IL-10 Year 2 | 630 | 10 | 18 | 0.89 | 0.91 | 0.02 (-0.07, 0.1) | 0.69 |
|  | Ln GM-CSF/IL-10 Year 2 | 652 | 10 | 18 | 2.33 | 2.33 | 0 (-0.12, 0.12) | 1 |
|  | Ln IL-2/IL-10 Year 2 | 558 | 10 | 18 | -2.39 | -2.41 | -0.02 (-0.16, 0.13) | 0.82 |
|  | Ln IFN-y Year 2 | 569 | 10 | 18 | 1.95 | 1.96 | 0 (-0.07, 0.08) | 0.98 |
|  | Ln CRP Year 2 | 1175 | 10 | 17 | -0.32 | -0.33 | -0.01 (-0.19, 0.17) | 0.9 |
|  | Ln AGP Year 2 | 692 | 10 | 18 | -0.19 | -0.18 | 0.01 (-0.04, 0.06) | 0.75 |
|  | Ln IGF-1 Year 2 | 671 | 10 | 18 | 3.9 | 3.88 | -0.02 (-0.08, 0.04) | 0.52 |
|  |  |  |  |  |  |  |  |  |
| Paternal stress score | Sum score of inflammation Year 2 | 459 | 15 | 22 | 0.14 | 0.2 | 0.06 (-0.06, 0.18) | 0.35 |
|  | Ln Th1/Th2 Year 2 | 422 | 15 | 21 | -0.01 | -0.03 | -0.03 (-0.08, 0.03) | 0.36 |
|  | Ln Th1/Th17 Year 2 | 477 | 15 | 22 | 0.35 | 0.32 | -0.03 (-0.09, 0.02) | 0.23 |
|  | Ln Th1/IL-10 Year 2 | 455 | 15 | 22 | 1.39 | 1.4 | 0.01 (-0.06, 0.08) | 0.81 |
|  | Ln Th2/IL-10 Year 2 | 467 | 15 | 22 | 1.46 | 1.48 | 0.01 (-0.07, 0.1) | 0.77 |
|  | Ln Th17/IL-10 Year 2 | 453 | 15 | 22 | 0.91 | 0.92 | 0.01 (-0.07, 0.1) | 0.8 |
|  | Ln GM-CSF/IL-10 Year 2 | 478 | 15 | 22 | 2.33 | 2.55 | 0.21 (-0.06, 0.48) | 0.12 |
|  | Ln IL-2/IL-10 Year 2 | 415 | 15 | 21 | -2.49 | -2.46 | 0.03 (-0.11, 0.17) | 0.69 |
|  | Ln IFN-y Year 2 | 423 | 14.5 | 21 | 2.05 | 2.04 | -0.01 (-0.09, 0.07) | 0.82 |
|  | Ln CRP Year 2 | 863 | 15 | 22 | -0.17 | -0.23 | -0.06 (-0.18, 0.06) | 0.33 |
|  | Ln AGP Year 2 | 525 | 15 | 22 | -0.21 | -0.17 | 0.05 (-0.01, 0.1) | 0.09 |
|  | Ln IGF-1 Year 2 | 422 | 15 | 21 | 3.74 | 3.78 | 0.04 (-0.01, 0.09) | 0.11 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.2 after adjusting for multiple comparisons using the Benjamini-Hochberg procedure | | | | | | | | |

## Table 3: Association between CES-D Scores at Year 1 and Child Immune Status

| CES-D Year 1 | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Adjusted | | | |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| CES-D Score Year 1 | Sum score of inflammation Year 1 | 582 | 6 | 16 | -0.05 | -0.05 | 0 (-0.1, 0.1) | 0.97 |
|  | Ln Th1/Th2 Year 1 | 577 | 6 | 16 | -0.02 | -0.01 | 0 (-0.05, 0.06) | 0.93 |
|  | Ln Th1/Th17 Year 1 | 571 | 6 | 16 | 0.31 | 0.42 | 0.12 (0.01, 0.22) | 0.03 |
|  | Ln Th1/IL-10 Year 1 | 579 | 6 | 16 | 1.06 | 1.05 | -0.02 (-0.07, 0.04) | 0.56 |
|  | Ln Th2/IL-10 Year 1 | 570 | 6 | 16 | 0.96 | 0.94 | -0.02 (-0.18, 0.13) | 0.76 |
|  | Ln Th17/IL-10 Year 1 | 570 | 6 | 16 | 0.67 | 0.56 | -0.11 (-0.26, 0.04) | 0.15 |
|  | Ln GM-CSF/IL-10 Year 1 | 490 | 6 | 16 | 1.96 | 2.06 | 0.1 (-0.16, 0.35) | 0.47 |
|  | Ln IL-2/IL-10 Year 1 | 571 | 6 | 16 | -2.7 | -2.6 | 0.1 (-0.02, 0.22) | 0.12 |
|  | Ln IFN-y Year 1 | 582 | 6 | 16 | 1.9 | 1.9 | -0.01 (-0.08, 0.07) | 0.89 |
|  | Ln CRP Year 1 | 453 | 6 | 15 | 0.15 | 0.22 | 0.07 (-0.02, 0.16) | 0.13 |
|  | Ln AGP Year 1 | 436 | 6 | 16 | 0.09 | 0.1 | 0.02 (-0.27, 0.3) | 0.92 |
|  | Ln IGF-1 Year 1 | 434 | 6 | 15 | 3.51 | 3.58 | 0.07 (-0.06, 0.2) | 0.29 |
|  |  |  |  |  |  |  |  |  |
|  | Sum score of inflammation Year 2 | 643 | 6 | 15 | 0.05 | 0.11 | 0.06 (-0.3, 0.43) | 0.76 |
|  | Ln Th1/Th2 Year 2 | 583 | 6 | 16 | -0.04 | -0.02 | 0.02 (-0.03, 0.07) | 0.47 |
|  | Ln Th1/Th17 Year 2 | 576 | 6 | 16 | 0.31 | 0.28 | -0.03 (-0.13, 0.08) | 0.61 |
|  | Ln Th1/IL-10 Year 2 | 637 | 6 | 15 | 1.37 | 1.35 | -0.01 (-0.04, 0.01) | 0.29 |
|  | Ln Th2/IL-10 Year 2 | 660 | 6 | 16 | 1.32 | 1.3 | -0.02 (-0.05, 0.02) | 0.33 |
|  | Ln Th17/IL-10 Year 2 | 630 | 6 | 15 | 0.87 | 0.88 | 0.01 (-1.48, 1.5) | 0.99 |
|  | Ln GM-CSF/IL-10 Year 2 | 662 | 6 | 16 | 2.39 | 2.38 | 0 (-0.09, 0.08) | 0.94 |
|  | Ln IL-2/IL-10 Year 2 | 575 | 6 | 16 | -2.43 | -2.44 | -0.01 (-0.14, 0.11) | 0.85 |
|  | Ln IFN-y Year 2 | 586 | 6 | 16 | 1.98 | 2 | 0.02 (-0.05, 0.08) | 0.6 |
|  | Ln CRP Year 2 | 1213 | 6 | 16 | -0.31 | -0.27 | 0.04 (0, 0.09) | 0.06 |
|  | Ln AGP Year 2 | 716 | 6 | 16 | -0.18 | -0.16 | 0.02 (0, 0.04) | 0.12 |
|  | Ln IGF-1 Year 2 | 661 | 6 | 16 | 3.85 | 3.88 | 0.02 (-0.06, 0.11) | 0.61 |
|  |  |  |  |  |  |  |  |  |
| Binary CES-D Score Year 1 | Sum score of inflammation Year 1 | 593 | 0 | 1 | 0.01 | -0.02 | -0.03 (-0.21, 0.15) | 0.78 |
|  | Ln Th1/Th2 Year 1 | 588 | 0 | 1 | 0.15 | 0.18 | 0.03 (-0.05, 0.11) | 0.5 |
|  | Ln Th1/Th17 Year 1 | 583 | 0 | 1 | 0.4 | 0.39 | -0.01 (-0.1, 0.08) | 0.88 |
|  | Ln Th1/IL-10 Year 1 | 590 | 0 | 1 | 1.11 | 1.1 | -0.01 (-0.11, 0.08) | 0.81 |
|  | Ln Th2/IL-10 Year 1 | 588 | 0 | 1 | 0.92 | 0.86 | -0.06 (-0.18, 0.05) | 0.3 |
|  | Ln Th17/IL-10 Year 1 | 582 | 0 | 1 | 0.68 | 0.67 | -0.01 (-0.14, 0.11) | 0.84 |
|  | Ln GM-CSF/IL-10 Year 1 | 591 | 0 | 1 | 1.64 | 1.67 | 0.03 (-0.14, 0.2) | 0.74 |
|  | Ln IL-2/IL-10 Year 1 | 582 | 0 | 1 | -2.67 | -2.58 | 0.09 (-0.12, 0.31) | 0.4 |
|  | Ln IFN-y Year 1 | 593 | 0 | 1 | 2.03 | 2.05 | 0.02 (-0.08, 0.11) | 0.73 |
|  | Ln CRP Year 1 | 541 | 0 | 1 | -0.1 | 0.11 | 0.2 (-0.11, 0.51) | 0.2 |
|  | Ln AGP Year 1 | 528 | 0 | 1 | -0.11 | -0.04 | 0.07 (-0.02, 0.15) | 0.11 |
|  | Ln IGF-1 Year 1 | 527 | 0 | 1 | 3.64 | 3.55 | -0.09 (-0.2, 0.03) | 0.14 |
|  |  |  |  |  |  |  |  |  |
|  | Sum score of inflammation Year 2 | 643 | 0 | 1 | 0.08 | -0.26 | -0.35 (-0.66, -0.04) | 0.03 |
|  | Ln Th1/Th2 Year 2 | 583 | 0 | 1 | -0.04 | 0 | 0.04 (-0.05, 0.13) | 0.42 |
|  | Ln Th1/Th17 Year 2 | 576 | 0 | 1 | 0.28 | 0.34 | 0.06 (-0.03, 0.15) | 0.17 |
|  | Ln Th1/IL-10 Year 2 | 637 | 0 | 1 | 1.37 | 1.39 | 0.01 (-0.15, 0.18) | 0.87 |
|  | Ln Th2/IL-10 Year 2 | 660 | 0 | 1 | 1.31 | 1.29 | -0.03 (-0.14, 0.08) | 0.65 |
|  | Ln Th17/IL-10 Year 2 | 630 | 0 | 1 | 0.91 | 0.92 | 0.01 (-0.35, 0.37) | 0.96 |
|  | Ln GM-CSF/IL-10 Year 2 | 662 | 0 | 1 | 2.39 | 2.36 | -0.03 (-0.2, 0.14) | 0.74 |
|  | Ln IL-2/IL-10 Year 2 | 575 | 0 | 1 | -2.41 | -2.54 | -0.14 (-0.36, 0.09) | 0.23 |
|  | Ln IFN-y Year 2 | 586 | 0 | 1 | 2 | 1.97 | -0.02 (-0.14, 0.09) | 0.71 |
|  | Ln CRP Year 2 | 1213 | 0 | 1 | -0.35 | -0.86 | -0.51 (-1.01, -0.01) | 0.05 |
|  | Ln AGP Year 2 | 716 | 0 | 1 | -0.18 | -0.13 | 0.06 (-0.08, 0.2) | 0.43 |
|  | Ln IGF-1 Year 2 | 661 | 0 | 1 | 3.88 | 3.88 | 0 (-0.08, 0.08) | 0.95 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.2 after adjusting for multiple comparisons using the Benjamini-Hochberg procedure | | | | | | | | |

## Table 4: Association between CES-D Scores at Year 2 and Child Immune Status

| CES-D Year 2 | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Adjusted | | | |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| CES-D Score Year 2 | Sum score of inflammation Year 2 | 643 | 5 | 17 | 0.06 | 0.09 | 0.02 (-0.15, 0.19) | 0.8 |
|  | Ln Th1/Th2 Year 2 | 565 | 5 | 17 | -0.06 | -0.05 | 0.01 (-0.04, 0.06) | 0.72 |
|  | Ln Th1/Th17 Year 2 | 559 | 5 | 17 | 0.29 | 0.3 | 0.01 (-0.04, 0.06) | 0.69 |
|  | Ln Th1/IL-10 Year 2 | 637 | 5 | 17 | 1.37 | 1.36 | -0.01 (-0.13, 0.12) | 0.93 |
|  | Ln Th2/IL-10 Year 2 | 638 | 5 | 17 | 1.37 | 1.34 | -0.02 (-0.1, 0.05) | 0.54 |
|  | Ln Th17/IL-10 Year 2 | 630 | 5 | 17 | 0.9 | 0.92 | 0.03 (-0.12, 0.17) | 0.73 |
|  | Ln GM-CSF/IL-10 Year 2 | 651 | 5 | 17 | 2.33 | 2.34 | 0.01 (-0.08, 0.09) | 0.89 |
|  | Ln IL-2/IL-10 Year 2 | 557 | 5 | 17 | -2.35 | -2.42 | -0.07 (-0.19, 0.05) | 0.25 |
|  | Ln IFN-y Year 2 | 568 | 5 | 17 | 1.97 | 1.98 | 0 (-0.06, 0.07) | 0.9 |
|  | Ln CRP Year 2 | 1174 | 5 | 17 | -0.32 | -0.35 | -0.03 (-0.13, 0.06) | 0.53 |
|  | Ln AGP Year 2 | 691 | 5 | 17 | -0.18 | -0.19 | -0.01 (-0.06, 0.03) | 0.64 |
|  | Ln IGF-1 Year 2 | 671 | 5 | 17 | 3.9 | 3.89 | -0.01 (-0.09, 0.07) | 0.86 |
|  |  |  |  |  |  |  |  |  |
| Binary CES-D Score Year 2 | Sum score of inflammation Year 2 | 643 | 0 | 1 | 0.02 | 0.13 | 0.12 (-0.07, 0.3) | 0.23 |
|  | Ln Th1/Th2 Year 2 | 565 | 0 | 1 | -0.05 | -0.06 | -0.01 (-0.11, 0.09) | 0.85 |
|  | Ln Th1/Th17 Year 2 | 559 | 0 | 1 | 0.29 | 0.3 | 0.01 (-0.08, 0.1) | 0.9 |
|  | Ln Th1/IL-10 Year 2 | 637 | 0 | 1 | 1.37 | 1.38 | 0.02 (-0.09, 0.12) | 0.79 |
|  | Ln Th2/IL-10 Year 2 | 638 | 0 | 1 | 1.36 | 1.33 | -0.03 (-0.15, 0.1) | 0.68 |
|  | Ln Th17/IL-10 Year 2 | 630 | 0 | 1 | 0.91 | 0.91 | 0 (-0.12, 0.13) | 0.99 |
|  | Ln GM-CSF/IL-10 Year 2 | 651 | 0 | 1 | 2.33 | 2.34 | 0.01 (-0.16, 0.18) | 0.92 |
|  | Ln IL-2/IL-10 Year 2 | 557 | 0 | 1 | -2.36 | -2.48 | -0.12 (-0.34, 0.11) | 0.32 |
|  | Ln IFN-y Year 2 | 568 | 0 | 1 | 1.94 | 1.98 | 0.05 (-0.07, 0.17) | 0.43 |
|  | Ln CRP Year 2 | 1174 | 0 | 1 | -0.32 | -0.37 | -0.05 (-0.23, 0.14) | 0.62 |
|  | Ln AGP Year 2 | 691 | 0 | 1 | -0.18 | -0.19 | -0.01 (-0.1, 0.08) | 0.83 |
|  | Ln IGF-1 Year 2 | 671 | 0 | 1 | 3.91 | 3.88 | -0.03 (-0.11, 0.05) | 0.5 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.2 after adjusting for multiple comparisons using the Benjamini-Hochberg procedure | | | | | | | | |